SHP2-interacting transmembrane adaptor protein (SIT), a novel disulfide-linked dimer regulating human T cell activation

T lymphocytes express several low molecular weight transmembrane adaptor proteins that recruit src homology (SH)2 domain-containing intracellular molecules to the cell membrane via tyrosine-based signaling motifs. We describe here a novel molecule of this group termed SIT (SHP2 interacting transmemb...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of experimental medicine Vol. 189; no. 8; pp. 1181 - 1194
Main Authors: Marie-Cardine, A, Kirchgessner, H, Bruyns, E, Shevchenko, A, Mann, M, Autschbach, F, Ratnofsky, S, Meuer, S, Schraven, B
Format: Journal Article
Language:English
Published: United States The Rockefeller University Press 19-04-1999
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:T lymphocytes express several low molecular weight transmembrane adaptor proteins that recruit src homology (SH)2 domain-containing intracellular molecules to the cell membrane via tyrosine-based signaling motifs. We describe here a novel molecule of this group termed SIT (SHP2 interacting transmembrane adaptor protein). SIT is a disulfide-linked homodimeric glycoprotein that is expressed in lymphocytes. After tyrosine phosphorylation by src and possibly syk protein tyrosine kinases SIT recruits the SH2 domain-containing tyrosine phosphatase SHP2 via an immunoreceptor tyrosine-based inhibition motif. Overexpression of SIT in Jurkat cells downmodulates T cell receptor- and phytohemagglutinin-mediated activation of the nuclear factor of activated T cells (NF-AT) by interfering with signaling processes that are probably located upstream of activation of phospholipase C. However, binding of SHP2 to SIT is not required for inhibition of NF-AT induction, suggesting that SIT not only regulates NF-AT activity but also controls NF-AT unrelated pathways of T cell activation involving SHP2.
Bibliography:Address correspondence to Burkhart Schraven, Institute for Immunology, Immunomodulation Laboratory, University of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany. Phone: 6221-56-4059; Fax: 6221-56-5541; E-mail: m53@popix.urz.uni-heidelberg.de
ISSN:0022-1007
1540-9538
DOI:10.1084/jem.189.8.1181